Aveanna Healthcare (NASDAQ:AVAH) Major Shareholder J.H. Whitney Equity Partners V Sells 12,496,077 Shares of Stock

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder J.H. Whitney Equity Partners V sold 12,496,077 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $11.50, for a total value of $143,704,885.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

J.H. Whitney Equity Partners V also recently made the following trade(s):

• On Friday, August 21st, J.H. Whitney Equity Partners V sold 2,250,000 shares of Aveanna Healthcare stock. The shares were sold at an average price of $11.50, for a total transaction of $25,875,000.00.
• On Tuesday, June 30th, J.H. Whitney Equity Partners V sold 2,419,035 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.01, for a total transaction of $19,376,470.35.
• On Wednesday, June 24th, J.H. Whitney Equity Partners V sold 919,389 shares of Aveanna Healthcare stock. The stock was sold at an average price of $8.00, for a total transaction of $7,355,112.00.
• On Wednesday, June 3rd, J.H. Whitney Equity Partners V sold 5,842,240 shares of Aveanna Healthcare stock. The shares were sold at an average price of $6.24, for a total transaction of $36,455,577.60.

Aveanna Healthcare Stock Performance

Aveanna Healthcare stock traded up $0.54 on Monday, reaching $13.70. 5,371,630 shares of the stock were exchanged, compared to its average volume of 1,804,159. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 4.47. Aveanna Healthcare Holdings Inc. has a twelve month low of $5.93 and a twelve month high of $13.98. The firm has a fifty day moving average price of $9.58 and a two-hundred day moving average price of $7.92. The stock has a market cap of $2.99 billion, a PE ratio of 11.14, a PEG ratio of 0.92 and a beta of 1.90.

Aveanna Healthcare (NASDAQ:AVAH) last announced its earnings results on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.05. The firm had revenue of $670.48 million during the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. Sell-side analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.68 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on AVAH shares. Raymond James Financial upped their target price on shares of Aveanna Healthcare from $13.00 to $15.00 and gave the company a “strong-buy” rating in a research note on Friday, August 14th. Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a report on Thursday, July 2nd. Wall Street Zen lowered shares of Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Barclays increased their target price on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Finally, BMO Capital Markets lifted their target price on Aveanna Healthcare from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Friday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Aveanna Healthcare has a consensus rating of “Moderate Buy” and a consensus price target of $12.89.

Aveanna Healthcare News Summary

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Royal Bank of Canada raised its price target for Aveanna Healthcare from $10 to $16 and upgraded the stock to “outperform.” The new target implies additional upside from recent trading levels, providing a bullish signal for AVAH. Benzinga analyst price-target report
• Neutral Sentiment: Truist Financial increased its price target from $11 to $15 but maintained a “hold” rating. The higher valuation suggests improved expectations, while the unchanged rating indicates the firm does not see a compelling reason to become more bullish after the stock’s recent advance. Benzinga analyst price-target report
• Negative Sentiment: Several insiders sold a combined 320,000 shares at an average price of $11.50, generating approximately $3.68 million. CEO Jeff Shaner sold 90,000 shares, director Rodney D. Windley sold 180,000, and insider Edwin C. Reisz sold 50,000. Each retained a substantial stake, but the coordinated sales—particularly Windley’s roughly 8% position reduction—could raise concerns about insider confidence or add near-term selling pressure. CEO insider sale filing Director insider sale filing Insider sale filing

Institutional Trading of Aveanna Healthcare

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Aveanna Healthcare during the second quarter worth approximately $63,504,000. Vanguard Group Inc. increased its holdings in Aveanna Healthcare by 38.0% in the fourth quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock valued at $45,564,000 after purchasing an additional 1,535,351 shares during the last quarter. Millennium Management LLC increased its stake in shares of Aveanna Healthcare by 1,007.1% in the 4th quarter. Millennium Management LLC now owns 1,114,717 shares of the company’s stock valued at $9,107,000 after acquiring an additional 1,014,030 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Aveanna Healthcare in the second quarter worth $7,881,000. Finally, Nuveen LLC raised its stake in Aveanna Healthcare by 135.9% during the 4th quarter. Nuveen LLC now owns 1,571,308 shares of the company’s stock worth $12,838,000 after buying an additional 905,316 shares during the period. Institutional investors and hedge funds own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.